From: The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
Study | Year | Location | Number (age)a | Drug (dosage) | Durationb |
---|---|---|---|---|---|
UDCA Monotherapy | |||||
Laurin et al. [24] | 1996 | USA | 25 (46 y) vs. 16 (50 y) | UDCA (13-15Â mg/kg/d)/Clofibrate (1Â g twice daily) | 12Â m |
Lindor et al. [25] | 2004 | USA/Canada | 80 (45.4 y) vs. 86 (48.5 y) | UDCA (13-15Â mg/kg/d)/placebo (tablet) | 24Â m |
Dufour et al. [20] | 2006 | Switzerland | 18 (47 y) vs. 15 (45 y) | UDCA (13-15Â mg/kg/d)/placebo (tablet) | 24Â m |
Kiyici et al. [26] | 2003 | Turkey | 17 (43.7 y) vs. 27 (50.2 y) | UDCA (13-15Â mg/kg/d)/Atorvastatin (10Â mg/d) | 6Â m |
Hong Qian, et al. [32] | 2007 | China | 26 vs. 26 | UDCA (15-20Â mg/kg/d)/polyene phosphatidylcholine (1368Â mg/d) | 6Â m |
Zhu Hong-juan [27] | 2010 | China | 30 (42.5 y) vs. 30 (43.6 y) | UDCA (750Â mg/d)/placebo (tablet) | 2Â m |
Ratziu et al. [28] | 2011 | France | 55 (49.8 y) vs. 61 (49.6 y) | UDCA (28-35Â mg/kg/d)/placebo (tablet) | 12Â m |
Leuschner et al. [29] | 2010 | Germany | 94 (41.5 y) vs. 91 (45.0 y) | UDCA (23-28Â mg/kg/d)/placebo (tablet) | 18Â m |
UDCA combined with other drugs | |||||
Dufour et al. [20] | 2006 | Switzerland | 15 (46 y) vs. 15 (45 y) | UDCA (13-15 mg/kg/d) + Vitamin E (400 IU/d)/placebo (tablet) | 24 m |
Zhuang Xue-shan [30] | 2009 | China | 40 vs. 42 | UDCA (750 mg/d) + polyene phosphatidylcholin (1368 mg/d)/polyene phosphatidylcholine (1368 mg/d) | 6 m |
Sun Yan [31] | 2007 | China | 76 vs. 61 | UDCA (300 mg/d) + Silymarin (231 mg/d)/Silymarin (231 mg/d) | 3 m |
Lv Hong [33] | 2005 | China | 40 vs. 40 | UDCA (450 mg/d) + glycyrrhizin (450 mg/d)/placebo (tablet) | 2 m |
Liu Zhi-ye [34] | 2006 | China | 96 (42.5 y) vs. 54 (47.6 y) | UDCA (900 mg/d) + Tiopronin (600 mg/d)/ UDCA (900 mg/d) | 3 m |